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disease areas and therapeutic classes, but treatments for musculoskeletal and 
rheumatic disease are evaluated most frequently.  
 
PRM190  
EXTENSION OF THE HOSMER-LEMESHOW GOODNESS OF FIT STATISTIC TO 
LINEAR MODELS WITH REPEATED MEASUREMENTS  
Li R1, Su Z2, Mendelsohn A2, Gemmen E1 
1Quintiles Outcome, Rockville, MD, USA, 2Quintiles Outcome, Cambridge, MA, USA  
OBJECTIVES: Studies of health outcomes commonly involve binary measures, 
assessed multiple times. Although generalized linear mixed (GLIMMIX) models 
are well suited for analyzing these data, there does not exist a formal statistic to 
assess the goodness of fit (GOF) for GLIMMIX models. We developed an extension 
of the Hosmer-Lemeshow GOF test used for logistic regression that can be 
applied to GLIMMIX models. METHODS: The correlation among repeated 
measurements of the binary outcome variable was accounted for by a random 
effect in the GLIMMIX model. The principles of Hosmer-Lemeshow method were 
followed. The linear unbiased estimate of dependent variables were transformed 
to the original probability, sorted from least to largest, and divided into deciles. A 
Chi-square statistic and corresponding p-value with eight degrees of freedom, 
was calculated based upon the expected and observed numbers among deciles. 
The proposed GOF test was validated by a simulation study with 1000 runs 
generated from logistic regression models with and without random effects. The 
results were compared with the Hosmer-Lemeshow GOF test in situations where 
the latter is appropriate. The proposed method was used in the analysis of a 
comparative effectiveness (CE) study of ophthalmologic treatments for open-
angle glaucoma patients. RESULTS: When there was no random effect, the 
proposed GOF test results from the GLIMMIX procedure were almost identical to 
those of Hosmer-Lemeshow GOF test from the logistic procedure. With a random 
effect built in a correctly specified model, the goodness of fit rejection rate was 
5.1%, which is close to the nominal level 5%. The proposed test did not indicate 
lack of fit for the regression models in the CE study. CONCLUSIONS: The 
proposed GOF test provides an assessment of model fit for models with binary 
outcomes and repeated measurements for predictor variables.  
 
PRM191  
ANNUAL HEALTH CARE CHARGES AND UTILIZATION IN ATRIAL FIBRILLATION 
(AF) PATIENTS ON DRONEDARONE COMPARED TO AMIODARONE  
Dahal A, Marrouche N, Ghate SR 
University of Utah, Salt Lake City, UT, USA  
OBJECTIVES: Amiodarone, a frequently used drug for AF patients, has been 
associated with severe adverse events. A relatively new drug, dronedarone, has 
been shown to reduce the risk of adverse events and duration of hospital stays in 
AF patients. The objective of this study was to assess the annual health care 
charges and utilization in AF patients on dronedarone compared to amiodarone. 
METHODS: Data from the University of Utah Enterprise Data Warehouse were 
analyzed for AF patients from October 2009 to October 2012. Eligible patients had 
a prescription for either amiodarone or dronedarone on index date; had 6 
months pre-index and 12 months post-index follow-up activity. Annual total 
charges and annual inpatient and outpatient visits were assessed during the 
follow-up period. Generalized linear model (GLM) with gamma distribution and 
log link and negative binomial model (NBM) were used to examine the annual 
charges and usage between the two groups, respectively, controlling for 
demographics, insurance status, baseline comorbidities, and prior drug use. 
RESULTS: Of the 1003 patients analyzed, 134 (13.4%) patients were prescribed 
dronedarone and 869 (86.6%) were prescribed amiodarone. The age and gender 
distribution was not significantly different between the two groups (p>0.05). The 
mean unadjusted annual health care charges for dronedarone were significantly 
lower compared to amiodarone ($40,395 vs. $96,387, p<0.05). The mean annual 
outpatient visits for dronedarone were significantly higher compared to 
amiodarone (7.96 vs. 4.78, p<0.05). GLM results indicate that dronedarone 
patients had 71% lower annual health care charges compared to amiodarone 
patients (coeff. -0.711, p<0.05). NBM results show that dronedarone patients were 
61% less likely to have inpatient visits (coeff. -0.61, p<0.05) and 39% more likely 
to have outpatient visits (coeff. 0.39, p<0.05) compared to amiodarone patients. 
CONCLUSIONS: The annual health care charges and inpatient visits were 
significantly lower but outpatient utilization was higher in dronedarone 
compared to amiodarone patients.  
 
PRM192  
USING PARAMETRIC SURVIVAL CURVES TO ESTIMATE PROGRESSION FREE 
SURVIVAL IN A NETOWRK META-ANALYIS OF TREATMENTS FOR CHRONIC 
LYMPHOCYTIC LEUKEMIA  
Devine B1, Cheng MM2 
1University of Washington, Seattle, WA, USA, 2Abbott Diabetes Care, Alamdea, CA, USA  
OBJECTIVES: When comparing survival time among competing treatments, the 
assumption of constant hazards, necessary for use of semi-parametric modeling 
techniques, cannot always be met. Use of a fully parametric model provides a 
more flexible approach and a better estimate of treatment effects. Using the 
results of our already published network meta-analysis, our objective is to focus 
on the use of parametric survival curves to estimate progression free survival 
(PFS) in patients with chronic lymphocytic leukemia. METHODS: We tested 
parametric Weibull and log-logistic regression models with a two-parameter 
relative treatment effect (scale and shape), to indirectly compare PFS from 
multiple trials. We scanned survival curves from each included study, and used 
data from each consecutive interval to calculate model parameters. We 
estimated the number of deaths using the binomial likelihood distribution. We 
conducted the network meta-analysis using Bayesian statistical methods. We fit 
fixed and random effects models, and modeled scale and shape parameters on 
the log hazard scale. We evaluated goodness-of-fit by visually inspecting the 
linearity of diagnostic plots and comparing deviance information criteria (DIC). 
Using parameter estimates from the posterior summary we derived hazard rates, 
hazard ratios (HRs) and PFS survival curves for each treatment. To estimate the 
mean duration of PFS for each treatment, we calculated the area under each PFS 
curve. RESULTS: Seven randomized controlled trials of five treatments were 
included. The fixed effects Weibull model was the best fit for the data, with 
stronger linearity in the diagnostic plots and a lower DIC value. Hazard rates, 
HRs, PFS, survival, and median survival, with 95% credible intervals, were 
calculated for each treatment. Results suggest the hazard of disease progression 
for two treatments was constant, and increased over time for the other three. 
CONCLUSIONS: Parametric survival methods are useful in comparing PFS in the 
oncology setting.  
 
PRM193  
APPLICATION OF RECLASSIFICATION MEASURES IN COMPARING RISK 
ADJUSTMENT MODELS  
Mehta HB, Mehta V, Girman CJ 
Merck, Sharp & Dohme, North Wales, PA, USA  
OBJECTIVES: A traditional statistical measure such as concordance(c) statistics 
has been used widely for comparison of risk adjustment models; however, c-
statistic has been criticized for its insensitivity. To overcome the limitations of c-
statistics, novel reclassification measures (reclassification calibration statistics, 
Net Reclassification Index (NRI) and Integrated Discrimination Index (IDI)) have 
recently been proposed. The objective was to compare Charlson Comorbidity 
Index (CCI), Chronic Disease Score (CDS) and CCI+CDS in predicting one year 
mortality in type-2 diabetes mellitus patients (T2DM) by applying novel 
reclassification measures. METHODS: The Clinical Practice Research Database, 
electronic medical record data from UK, was used for this retrospective 
longitudinal cohort study. Patients diagnosed with T2DM from January 1, 2006 to 
December 31, 2006 were included. Diagnosis and prescription information upto 
1-year prior to the index date, i.e. first date of T2DM diagnosis, was used to 
create CCI and CDS, respectively. Patients were followed for 1 year from the 
index date to observe mortality. Descriptive statistics was used to describe the 
study cohort. In addition to traditional c-statistics from logistics regression, NRI 
and IDI were used to compare risk adjustment models. RESULTS: The cohort 
consisted of 26,191 patients with T2DM. The mean CCI and CDS were 0.24±0.67 
and 1.58±1.06, respectively. The c-statistics values for CCI, CDS and CCI+CDS 
models were 0.791 (95%CI: 0.777-0.805), 0.788 (95%CI: 0.774-0.802) and 0.803 
(95%CI: 0.789-0.817), respectively. The CDS and CCI+CDS reclassified 1.92% 
(p=0.238) and 6.50% (p=<0.001) patients into correct strata compared to the  
CCI. The IDI values for CDS and CCI+CDS were -0.64% (p=<0.001) and 0.43 
(p=<0.001). This means that addition of CDS in CCI improved the prediction of 
mortality. CONCLUSIONS: Combined score (CCI + CDS) performed better than 
individual scores. In addition to c-statistics, reclassification measures such as 
NRI and IDI can be added to the armamentarium of risk adjustment model 
comparisons.  
 
PRM194  
MATCHING-ADJUSTED INDIRECT COMPARISONS: A SIMULATION STUDY OF 
STATISTICAL PERFORMANCE  
Signorovitch J, Ayyagari R, Cheng D, Wu EQ 
Analysis Group, Inc., Boston, MA, USA  
OBJECTIVES: When indirectly comparing treatments across separate clinical 
trials, matching-adjusted indirect comparisons (MAICs) can help avoid bias due 
to cross-trial differences in baseline characteristics. The approach uses 
propensity scores to adjust individual patient data from trials of one treatment 
to match published baseline characteristics from trials of comparator 
treatments. We assessed the statistical properties of MAIC, including the 
accuracy of estimated treatment effects and their standard errors, in a 
simulation study. METHODS: Each simulation scenario included two randomized 
controlled trials with a common control arm and a dichotomous outcome. 
Sample sizes ranged from 125 to 1000 patients per arm. Cross-trial differences in 
baseline characteristics were simulated to generate low, moderate and high 
levels of potential bias. For each simulated dataset, MAIC was used to estimate 
the relative treatment effect using individual patient data from one trial and 
aggregate data from the other. Estimated treatment effects and standard errors 
were evaluated for accuracy across 1000 simulations. Indirect comparisons 
without matching adjustment were evaluated in parallel. RESULTS: By design, 
indirect comparisons without matching exhibited biases ranging from 10% to 
200% of the true treatment effect across simulation scenarios. In contrast, the 
MAIC estimators exhibited negligible bias, falling within +/- 2% of the true 
treatment effect when all confounding variables were considered. The sandwich 
estimator closely approximated the true standard errors, and was slightly 
conservative, overestimating by as much as 8%, but usually less than 5%. These 
findings were consistent across the range of investigated sample sizes and levels 
of confounding. CONCLUSIONS: MAIC can remove bias due to observed cross-
trial differences and provide reliable assessments of statistical uncertainty for 
indirect comparisons that combine individual patient data and aggregate data.  
 
PRM195  
BAYESIAN MODELS WITH A WEAKLY INFORMATIVE PRIOR: A USEFUL 
ALTERNATIVE FOR SOLVING SPARSE DATA PROBLEMS  
Soliman AM1, MacLehose RF2, Carlson A3 
1College of Pharmacy, University of Minnesota, Minneapolis, MN, USA, 2University of Minnesota, 
Minneapolis, MN, USA, 3Data Intelligence Consultants, LLC, Eden Prairie, MN, USA  
OBJECTIVES: Separation problems (perfect prediction of a binary outcome by one 
or more covariates) are common in health outcomes research in high prevalence, 
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sparse data structures. Separation often leads to failure in convergence of 
maximum likelihood models or unrealistic parameter estimates with wide 
confidence intervals. Therefore, the study objective is to compare the empirical 
performance of alternative methods for modeling sparse data in the context of 
small sample sizes: Firth-bias corrected logistic regression, exact logistic 
regression, penalized logistic regressions macro implemented in STATA, removal 
of the variable causing separation, and a Bayesian logistic model with a weakly 
informative prior (WIP). METHODS: HIPAA compliant diabetes patient records 
were used for determining factors associated with exposure to Medication 
Therapy Management (MTM) services at high frequency. Potential predictors of 
MTM visit frequency included age, gender, medication regimen complexities and 
presence of diabetes-related complications. This dataset had a small sample size 
(n=121) and exhibited separation problem; all patients in the high visit frequency 
group had diabetes with complexity. We compared the results of the Bayesian 
model with a WIP (coefficients are assigned a N(0,1.38) prior) to results of 
deleting the problematic variable, exact logistic regression and two different 
algorithms for penalized log likelihood functions (Firth’s Bias-Correction in SAS 
and a STATA-Macro based routine). RESULTS: The Bayesian model with WIP 
produced odds ratio estimates of high frequency group membership based on 
diabetes complexity within expected range of treatment effects and plausible 
confidence intervals OR=4.64 (CI:0.98, 24.58). Among other models, only Firth-
Bias model converged but parameter estimates and confidence intervals were 
unrealistically large OR=210.9 (CI:1.83, >999.99). Removal of the problematic 
variable (diabetes complexity) from the model prevented assessment of its effect 
on the probability of high visit frequency membership. CONCLUSIONS: Bayesian 
models with WIP represent a useful tool for modeling health outcomes sparse 
data with small sample size.  
 
PRM196  
HOW LOW CAN WE GO?–MAKING MEANINGFUL INFERENCES FROM SMALL 
SAMPLES  
Bakken DG, Bond M 
KJT Group, Inc., Honeoye Falls, NY, USA  
OBJECTIVES: To explore the impact of inferences from very samples on the 
outcome of management decisions. In many cases management has some prior 
belief about the states of nature. We explore the potential advantage of 
incorporating Bayesian inference to improve the confidence in managerial 
decisions based on small samples.. Traditionally, survey researchers reconcile 
differences between survey results and prior beliefs by citing the uncertainty 
reflected in the sampling error or looking for other explanatory factors (such as 
possible survey measurement error). The Bayesian approach integrates the 
different sources of information (i.e., prior belief and observed survey results) to 
arrive at the most probable estimate. In full realization, a Bayesian approach 
considers not just the probability that “truth” lies outside some range of values 
but seeks to estimate the probability of each of many possible hypotheses, given 
the data was that obtained. METHODS: Using responses to a choice-based 
conjoint exercise that was embedded in an online survey of approximately 700 
individuals, we created a series of samples of different sizes using different 
restrictions to reflect the ways in which both probability and convenience 
samples might be generated. We drew multiples of ten random samples of 25, 
50, 75, 100, 150, 225 and 450 from our “population” of 897 respondents, resulting 
in 70 individual samples. We estimated HB models for each sample (using 
Sawtooth Software’s CBC-HB program). RESULTS: Simulated choice 
probabilities–a key output of discrete choice models–stabilize across samples 
starting with n=75. For smaller samples, decision confidence can be increased 
using Bayesian inference and bootstrapping methods. CONCLUSIONS: 
Meaningful inferences—and hence decisions–can be made with smaller sample 
sizes by utilizing Bayesian inference and methods such as bootstrapping to 
better estimate the degree of uncertainty in the data.  
 
PRM199  
UNDERESTIMATION OF UNCERTAINTIES IN HEALTH UTILITIES DERVIED  
FROM MAPPING ALGORITHMS INVOLVING HEALTH-RELATED QUALITY OF  
LIFE MEASURES: STATISTICAL EXPLANATIONS AND POTENTIAL  
REMEDIES  
Chan K1, Willan A2, Gupta M3, Pullenayegum E3 
1University of Toronto, Toronto, ON, Canada, 2Dalla Lana School of Public Health, Toronto, ON, 
Canada, 3McMaster University, Hamilton, ON, Canada  
OBJECTIVES: Health utilities (HUs) are required to conduct cost-utility analyses 
(CUAs). Often, health-related quality of life (HRQOL) data, instead of HUs, are 
collected in clinical trials. Increasingly, mapping algorithms have been 
developed to derive HUs from HRQOL data. However, the variance of the derived 
HUs based on mapping are observed to be smaller than those of the actual HUs. 
METHODS: Two reasons are proposed: (1) the presence of important 
unmeasured predictors leading to a high degree of unexplained variance of 
derived HUs, and (2) ignoring that the regression coefficients are random 
variables themselves. We derive three variance estimators of HUs to account for 
these reasons: (1) R2-adjusted estimator, (2) parametric estimator and (3) non-
parametric estimator. We tested these estimators using a simulated dataset and 
a real dataset involving EQ-5D and University of Washington Quality of Life 
questionnaire for patients with head and neck cancers. RESULTS: The R2 
adjusted estimator can be used in ordinary least square (OLS) based mapping 
algorithms and requires only the R2from the derivation study. The parametric 
estimator can be used in OLS based mapping algorithms and requires the mean 
square error (MSE) and the design matrix from the derivation study. The non-
parametric estimator can be used in any mapping algorithm and requires leave-
one-out cross-validation MSE from the derivation study. In the simulated 
dataset, all three estimators are within 1% of the variance of the actual HUs. In 
the real dataset, the unadjusted variance was 44% less than the actual variance, 
while all three estimators are within 10% of the actual variance. CONCLUSIONS: 
When conducting CUA based on mapping algorithms, the variance of derived 
HUs should be properly adjusted using one of the proposed methods so that the 
results of the CUA will have the appropriate degree of uncertainty.  
 
PRM200  
USING THE WEIGHTED INTERVAL MIDPOINT ESTIMATOR (WIME) TO 
ESTIMATE A POPULATION MEAN FROM INTERVAL DATA  
Magyar AF1, Wang B1, Furnback WE2 
1Alliance Life Sciences, Somerset, NJ, USA, 2Alliance Life Sciences Consulting Group, Jersey City, 
NJ, USA  
OBJECTIVES: In survey questions where the variable of interest is quantitative, 
responses often involve selecting one of several mutually exclusive intervals in 
which the variable lies within (denoted interval data). This precludes one from 
using many of the popularly reported measures of center (mean, median, mode, 
etc.). To this end, a simple estimator is proposed to estimate the population 
mean, μ, when the data are intervaled and its properties are studied. METHODS: 
For estimation of μ given intervaled data, we propose the Weighted Interval 
Midpoint Estimator (WIME). Expressions for its expected value and variance are 
derived. These are then calculated for normal distributions and a χ2 distribution 
on 1 degree of freedom using various interval configurations. Bootstrapping 
methods are then proposed to obtain estimates of the sampling distribution of 
the WIME as well as the sample mean given the interval counts. RESULTS:  
In general, the WIME is a biased estimator of μ; this bias is the same for all 
sample sizes. Simple bounds for the bias can derived. Both the bias and variance 
of the estimator depend on the choice of intervals. In the case of the normal 
distribution, equal-length intervals produce estimates with seemingly no  
bias and variance slightly above that of the sample mean as opposed to a  
non-equal-length configuration, even if the intervals are not symmetric about  
μ. For the χ2 distribution on 1 degree of freedom, using equal-length intervals 
produces estimates with less bias and variance than when using non- 
equal-length intervals. CONCLUSIONS: While the WIME is a quick and  
easy method to estimate μ, its performance depends on the intervals chosen. 
Thus prudence must be taken when selecting them. In the event no prior 
information exists to guide the process, equal-length intervals seem to be a safe 
fallback.  
 
PRM201  
A CAUTION ABOUT USING SAMPLE MEANS TO ESTIMATE INCREMENTAL 
COSTS FOR EXPENDITURES THAT FOLLOW A TRADITIONAL GAMMA 
DISTRIBUTION WITH PARAMETERS FOR SCALE AND SHAPE  
Juneau P 
Truven Health Analytics, Boyds, MD, USA  
OBJECTIVES: 1) To examine the practice of calculating a sample mean cost for 
each of two or more cohorts, reporting the difference(s) as the incremental 
cost(s), and reconciling this practice against the common assumption that the 
underlying expenditures follow a two-parameter gamma distribution, and 2) To 
revisit the interpretation of incremental costs based on the difference in sample 
means as the properties of the assumed underlying gamma distribution vary. 
METHODS: Monte Carlo gamma distribution simulation in SAS version 9.3 
varying the shape and scale parameters for the simulations and displaying the 
results in graphical and tabular format. RESULTS: It is possible to create 
examples of simulated data sets where the sample means have values that can 
be in excess of the estimated 75th percentile. CONCLUSIONS: An analyst should 
be cautious in his or her reporting of incremental costs as the lay consumer of 
these quantities may interpret the difference in the means like they would for 
two or more somewhat symmetrical distributions where the mean can represent 
the center. However, this interpretation might be misleading depending on the 
magnitude of the shape and scale parameters that characterize an underlying 
distribution's behavior.  
 
PRM203  
BAYESIAN MIXED TREATMENT COMPARISON (MTC): A NOVEL METHOD TO 
DEMONSTRATE EQUIVALENCE AND NON-INFERIORITY  
Malcolm WA, Uthman OA 
Novartis UK, Frimley, UK  
OBJECTIVES: When evaluating multiple drugs for equivalence (or non-
inferiority) within the context of a Bayesian MTC, most studies base their 
interpretation solely on the point estimates and respective credible intervals. 
The following novel methodology advances interpretation by: Incorporating a 
pre-specified minimal clinically important difference (MCID); presenting a direct 
probability of equivalence (or non-inferiority), and graphically depicting how the 
probability varies by MCID. METHODS: As an illustrative example, we applied 
MTC to compare 12-week HbA1c reduction with vildagliptin 50 mg bid vs. 
sitagliptin 100 mg qd as monotherapies in patients with type 2 diabetes. 
Equivalence was assessed with a predefined equivalence margin of MCID. A 
Bayesian approach has the advantage of being able to provide probability 
statements for equivalence, to make direct inferential statement that the 
treatment effect between the two comparisons is between the specified lower 
and upper MCID (HbA1c ±0.7). The posterior probability of equivalence is 
calculated based on the area under the curve between lower and upper MCID on 
distribution of the mean change in HbA1c between the two comparisons. 
Sensitivity analysis was conducted by varying MCID values. RESULTS: The 
results of the MTC showed no significance difference between the two 
interventions in the reduction of HbA1c at 12 weeks (Δ = 0.16; 95% CrI -0.20 to 
0.52). However, this evidence of “no significant difference” does not prove 
equivalence. Applying the new method, at 12 weeks follow-up, the probability 
